FDA Cardio-Renal Drugs Panel Will Discuss Pre-Dialysis Use For Phosphate Binders
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oct. 16-17 meeting will also discuss data requirements, study designs for pediatric indication for Pfizer’s Revatio in PAH.
You may also be interested in...
Genzyme Gets Mixed Results On Renvela Powder Formulation
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.
Amgen Gains Phase II Phosphate Binder With Acquisition of Ilypsa
Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.
Genzyme Will Look To Differentiate Renvela With Improved Dosing
Firm will also try to expand patient population for Renagel follow-on to predialysis setting, Renal Division head tells “The Pink Sheet” DAILY.